CymaBay submits New Drug Application for PBC treatment
Seeking a Priority Review designation, CymaBay anticipates that the FDA will conclude its evaluation of the PBC treatment within six months.
News
-
-
Study shows high and variable prevalence of PBC in the US
The prevalence of primary biliary cholangitis (PBC) in the U.S. may be high and variable between regions, according to a recent study.
-
High blood fat in PBC may not affect blood vessels and liver health
High blood levels of fats such as triglycerides and cholesterol in patients with PBC may not increase their risk for cardiovascular disease.
- My own advocate: How I fought for my health and won
- It’s a scary time for people with PBC, but hope isn’t lost
- A new nonprofit, a new conference and a new role
From the
PBC Ambassador
PBC Ambassador
Learn more about PBC
Sign up for the latest news, perspectives, and information about PBC.
